Thomas Kaley

15.8k total citations · 1 hit paper
83 papers, 2.6k citations indexed

About

Thomas Kaley is a scholar working on Genetics, Neurology and Oncology. According to data from OpenAlex, Thomas Kaley has authored 83 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Genetics, 27 papers in Neurology and 27 papers in Oncology. Recurrent topics in Thomas Kaley's work include Glioma Diagnosis and Treatment (48 papers), Brain Metastases and Treatment (16 papers) and Meningioma and schwannoma management (14 papers). Thomas Kaley is often cited by papers focused on Glioma Diagnosis and Treatment (48 papers), Brain Metastases and Treatment (16 papers) and Meningioma and schwannoma management (14 papers). Thomas Kaley collaborates with scholars based in United States, Australia and Switzerland. Thomas Kaley's co-authors include Lisa M. DeAngelis, Patrick Y. Wen, Michael McDermott, David Schiff, Igor T. Gavrilovic, Igor J. Barani, Antonio Omuro, Leland Rogers, Damien C. Weber and Craig Nolan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Thomas Kaley

77 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review

2014 465 citations Thomas Kaley, David Schiff et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Kaley United States	24	1.2k	1.1k	1.1k	485	408	83	2.6k
Ho Jun Seol South Korea	28	877 0.7×	936 0.8×	805 0.7×	523 1.1×	670 1.6×	148	3.1k
Elena Mazza Italy	24	722 0.6×	603 0.5×	508 0.5×	442 0.9×	539 1.3×	62	2.0k
Martin J. Rutkowski United States	30	783 0.6×	1.5k 1.3×	1.2k 1.1×	382 0.8×	810 2.0×	84	3.2k
María Dolores Tabernero Spain	28	824 0.7×	626 0.6×	425 0.4×	373 0.8×	286 0.7×	68	2.2k
Matthieu Peyre France	25	652 0.5×	930 0.8×	826 0.7×	125 0.3×	339 0.8×	83	1.8k
Ari J. Kane United States	27	472 0.4×	1.2k 1.0×	893 0.8×	214 0.4×	675 1.7×	50	2.1k
Benjamin Brokinkel Germany	24	791 0.6×	860 0.8×	692 0.6×	94 0.2×	275 0.7×	77	1.7k
Jason Fangusaro United States	28	1.4k 1.1×	314 0.3×	904 0.8×	359 0.7×	547 1.3×	102	2.5k
Sean Grimm United States	24	1.2k 1.0×	315 0.3×	900 0.8×	416 0.9×	134 0.3×	79	2.1k
Marian C. Neidert Switzerland	22	599 0.5×	382 0.3×	485 0.4×	287 0.6×	259 0.6×	108	1.8k

Countries citing papers authored by Thomas Kaley

Since Specialization

Citations

This map shows the geographic impact of Thomas Kaley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Kaley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Kaley more than expected).

Fields of papers citing papers by Thomas Kaley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Kaley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Kaley. The network helps show where Thomas Kaley may publish in the future.

Co-authorship network of co-authors of Thomas Kaley

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Kaley. A scholar is included among the top collaborators of Thomas Kaley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Kaley. Thomas Kaley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lin, Andrew, Vasilisa A. Rudneva, Nazanin Majd, et al.. (2025). Immune Checkpoint Inhibitor Therapy for Aggressive Pituitary Neuroendocrine Tumors. The Journal of Clinical Endocrinology & Metabolism. 110(11). 3066–3073. 5 indexed citations

Grommes, Christian, Elena Pentsova, Lauren Schaff, et al.. (2023). Preclinical and clinical evaluation of Buparlisib (BKM120) in recurrent/refractory Central Nervous System Lymphoma. Leukemia & lymphoma. 64(9). 1545–1553. 5 indexed citations

Page, David B., Kathryn Beal, Stefanie N. Linch, et al.. (2022). Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases. npj Breast Cancer. 8(1). 50–50. 25 indexed citations

Schaff, Lauren, Andrew Lin, Subhiksha Nandakumar, et al.. (2022). Combination Olaparib and Temozolomide for the Treatment of Glioma. Neurology. 99(17). 750–755. 7 indexed citations

Rudà, Roberta, David Capper, Adam Waldman, et al.. (2022). EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors. Neuro-Oncology. 24(12). 2015–2034. 34 indexed citations

Lin, Andrew, Alexandra Miller, Igor T. Gavrilovic, et al.. (2022). Concurrent Olaparib and Temozolomide for Recurrent Glioma (P5-9.005). Neurology. 98(18_supplement).

Coffee, Elizabeth, Thomas Kaley, Eli L. Diamond, Alexandra Miller, & Lauren Schaff. (2022). BRAFV600E-mutant glioblastoma responds to combination BRAF/MEK inhibition with encorafenib and binimetinib (P5-9.007). Neurology. 98(18_supplement).

McFaline-Figueroa, J Ricardo, Thomas Kaley, Ian F. Dunn, & Wenya Linda Bi. (2021). Biology and Treatment of Meningiomas. Hematology/Oncology Clinics of North America. 36(1). 133–146. 2 indexed citations

Graham, Maya Srikanth, Simone Krebs, Tejus Bale, et al.. (2020). Value of [18F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab. Neuro-Oncology Advances. 2(1). vdaa050–vdaa050. 6 indexed citations

10.

Umemura, Yoshie, Diane Wang, Kyung K. Peck, et al.. (2019). DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy. Journal of Neuro-Oncology. 146(2). 339–346. 22 indexed citations

11.

Gavrilovic, Igor T., et al.. (2019). Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas. Journal of Neuro-Oncology. 145(1). 57–63. 12 indexed citations

12.

Kaley, Thomas, Katherine S. Panageas, Ingo K. Mellinghoff, et al.. (2019). Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. Journal of Neuro-Oncology. 144(2). 403–407. 43 indexed citations

13.

Hyman, David M., Naiyer A. Rizvi, Ronald B. Natale, et al.. (2018). Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. Clinical Cancer Research. 24(12). 2749–2757. 38 indexed citations

14.

Boire, Adrienne, Qing Chen, Mariza Daras, et al.. (2017). Targeting carcinoma–astrocyte gap junctions in brain metastasis (S41.005). Neurology. 88(16_supplement).

15.

Grommes, Christian, Igor T. Gavrilovic, Thomas Kaley, et al.. (2016). Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Annals of Oncology. 27. vi105–vi105. 13 indexed citations

16.

Arévalo‐Pérez, Julio, Alissa A. Thomas, Thomas Kaley, et al.. (2015). T1-Weighted Dynamic Contrast-Enhanced MRI as a Noninvasive Biomarker of Epidermal Growth Factor Receptor vIII Status. American Journal of Neuroradiology. 36(12). 2256–2261. 41 indexed citations

17.

Kaley, Thomas, Patrick Y. Wen, David Schiff, et al.. (2014). Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro-Oncology. 17(1). 116–121. 194 indexed citations

18.

Nayak, Lakshmi, Fábio M. Iwamoto, Jeremy Rudnick, et al.. (2012). Atypical and anaplastic meningiomas treated with bevacizumab. Journal of Neuro-Oncology. 109(1). 187–193. 136 indexed citations

19.

Omuro, Antonio, Timothy A. Chan, Lauren E. Abrey, et al.. (2012). Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro-Oncology. 15(2). 242–250. 74 indexed citations

20.

Khasraw, Mustafa, et al.. (2010). SURVIVAL AND TREATMENT OF CRANIAL METASTASES (CMS) FROM NEUROENDOCRINE TUMORS (NETS) AT MEMORIAL SLOAN-KETTERING CANCER CENTER (MSKCC). Neuro-Oncology. 46–46. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact